Individuals currently or previously treated with insulin on a regular basis, with recurrent severe hypoglycaemia or hypoglycaemia unawareness, blood pressure outside 90159 mmHg (systolic) or 5099 mmHg (diastolic), or history of or presence of clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal or endocrinological conditions (except mild complications associated with diabetes), as well as pregnant women, were excluded from participation
J Pharm Exp Therap 162(1):10-20
The FDA has warned that these knockoff versions sometimes contain illicit semaglutide or tirzepatidethe active pharmaceutical ingredients (APIs) in weight loss drugs
When considering oral tirzepatide for weight loss, it's crucial to understand the importance of FDA approval
Over time, this can affect muscle mass, metabolism, and nutrient status